ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1487

A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy

Craig Wiesenhutter1,2, Rakesh Patel3, John Lavery4, Nighat Tahir5,6, Lydie Hazan7, Alan Kivitz8, Elizabeth Bretton9 and Jeffrey Kaine10, 1University of Washington School of Medicine, Seattle, WA, 2Coeur d’Alene Arthritis Clinic, Coeur d’Alene, ID, 3PMG Research of Salisbury, Salisbury, NC, 4Allen Arthritis and Allergy, Allen, TX, 5Community Hospital of Anderson and Madison County, Inc., Anderson, IN, 6Community Rheumatology of Anderson, Anderson, IN, 7Axis Clinical Trials, Los Angeles, CA, 8Altoona Center for Clinical Research, Duncansville, PA, 9Albuquerque Clinical Trials, Albuquerque, NM, 10Sarasota Arthritis Center, Sarasota, FL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: clinical trials, rheumatoid arthritis (RA) and safety

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Staphylococcal protein A (SpA) binds with high affinity to the Fc region of human immunoglobulin G and also to the Fab framework region of immunoglobulin encoded from genes of the VH3 family. At intravenous doses up to 1.5 µg/kg weekly SpA was found to have an acceptable safety profile in a Phase I rheumatoid arthritis (RA) trial. The current Phase I study evaluates the safety and effect on RA disease activity of 6 months of SpA treatment.

Methods

This study enrolled 61 RA patients (pts) at 8 US centers. In Part 1 of the study, 41 pts received 5 weekly doses of either placebo, 1.5, 3, 6 or 12 µg/kg of SpA. Partial results from Part 1 have been reported previously [1]. In Part 2, pts received placebo or a fixed SpA dose of either 240 µg or 420 µg given as 5 weekly doses followed by ‘maintenance’ doses at weeks 8, 12, 16 and 20 (6 months’ total treatment). Adverse events (AEs), pharmacokinetics, anti-SpA antibodies and disease activity (ACR20/50/70, DAS28-CRP, and CDAI [Clinical Disease Activity Index]) are being evaluated over the course of this ongoing study.

Results

Twenty pts were randomized in Part 2: 3 pts (240 µg), 12 pts (420 µg) and 5 pts (placebo). All AEs were Grade 1 or 2 in severity with the exception of 1 pt who experienced Grade 3 influenza (unrelated to treatment) and 1 pt with Grade 3 worsening of arthritis (related to treatment). 9 pts (45%) had related AEs, the most common being transient flare of musculoskeletal symptoms usually occurring 1–3 days post-infusion. In Parts 1 and 2 of the study, there were no deaths or serious AEs considered to be related to SpA. Nine of the 12 pts in the 420 µg SpA arm met per-protocol criteria for efficacy evaluation. For comparative purposes, the control group was pooled from the 15 placebo pts enrolled in Parts 1 and 2; 13 placebo pts met per-protocol criteria for efficacy evaluation. Of the 9 pts in Part 2 that received 420 µg SpA, 56% achieved ACR20 at day 113 vs. 31% of pts in the control group (see table). A similar pattern was seen with the ACR50: on day 113, 33% of 9 SpA-treated pts attained an ACR50 vs. 8% of pts in the control group. 

ACR20 Responders: 420 µg SpA  vs. Placebo

 

Study Day

1

8

15

22

29

43

57

85

113

SpA 420 µg (9 pts)

0%

0%

38%

63%

50%

33%

50%

56%

56%

Placebo (13 pts)

0%

11%

31%

23%

31%

25%

39%

39%

31%

CDAI data also indicated some reduction in disease activity, as 44% of 420 µg pts achieved a CDAI of ≤14 on 3 or more consecutive visits vs. 23% of pts in the control group. SpA and control pts had MDHAQ mean physical function scores of 3.57 and 3.59, respectively, at baseline. By day 85, the change from baseline was –1.17 and –0.59 for SpA and control pts, respectively. At day 113, the change from baseline was –1.38 vs. –0.6, respectively.

Conclusion

  • A 6-month regimen of 5 weekly infusions of SpA followed by 4 monthly ‘maintenance’ infusions had an acceptable safety profile in pts with RA. The most common AEs seemed to be associated with transient worsening of musculoskeletal symptoms.
  • During a 6-month study period, SpA appeared to result in some reduction in disease activity. Some patients experienced improvements.

 1.  Ann Rheum Dis 2014;73(Suppl2)


Disclosure:

C. Wiesenhutter,
None;

R. Patel,

Takeda, Exgen,

8;

J. Lavery,
None;

N. Tahir,
None;

L. Hazan,

Axis Clinical Trials, South Florida Clinical Trials, New York Clinical Trials, Impact Clinica Trials,

4;

A. Kivitz,
None;

E. Bretton,
None;

J. Kaine,

Pfizer Inc, Bristol-Myers-Squibb,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-1-dose-ranging-repeated-dose-trial-of-parenteral-staphylococcal-protein-a-prtx-100-in-patients-with-active-rheumatoid-arthritis-on-methotrexate-or-leflunamide-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology